Scott Auerbach
Concepts (387)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 40 | 2025 | 714 | 7.720 |
Why?
| | Heart-Assist Devices | 20 | 2025 | 559 | 3.690 |
Why?
| | Heart Failure | 25 | 2025 | 2088 | 2.760 |
Why?
| | Graft Rejection | 13 | 2025 | 544 | 2.170 |
Why?
| | Graft Survival | 11 | 2025 | 499 | 2.060 |
Why?
| | Toxicity Tests | 7 | 2025 | 42 | 1.200 |
Why?
| | Muscular Dystrophy, Duchenne | 5 | 2025 | 87 | 1.150 |
Why?
| | Heart Defects, Congenital | 11 | 2025 | 875 | 1.140 |
Why?
| | Cardiomyopathies | 10 | 2025 | 330 | 1.120 |
Why?
| | Child | 56 | 2025 | 22308 | 1.060 |
Why?
| | Heart Diseases | 3 | 2023 | 335 | 1.030 |
Why?
| | Gene Expression Profiling | 9 | 2025 | 1764 | 1.020 |
Why?
| | Transcriptome | 11 | 2025 | 1003 | 1.010 |
Why?
| | Liver | 8 | 2024 | 1819 | 1.000 |
Why?
| | Toxicogenetics | 5 | 2023 | 6 | 0.880 |
Why?
| | Glomerular Filtration Rate | 2 | 2024 | 750 | 0.830 |
Why?
| | Steroids | 2 | 2015 | 163 | 0.820 |
Why?
| | Myocarditis | 2 | 2023 | 100 | 0.790 |
Why?
| | Carcinogens | 4 | 2022 | 127 | 0.790 |
Why?
| | Child, Preschool | 26 | 2025 | 11457 | 0.740 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2025 | 623 | 0.720 |
Why?
| | Immunosuppressive Agents | 5 | 2025 | 854 | 0.680 |
Why?
| | Toxicology | 4 | 2025 | 44 | 0.680 |
Why?
| | Registries | 15 | 2025 | 2135 | 0.670 |
Why?
| | Kidney Transplantation | 2 | 2023 | 675 | 0.660 |
Why?
| | Adolescent | 36 | 2025 | 22007 | 0.640 |
Why?
| | Environmental Pollutants | 4 | 2025 | 165 | 0.630 |
Why?
| | Organ Transplantation | 4 | 2024 | 250 | 0.620 |
Why?
| | Small Molecule Libraries | 2 | 2017 | 98 | 0.610 |
Why?
| | Liver Neoplasms, Experimental | 2 | 2018 | 26 | 0.600 |
Why?
| | Humans | 94 | 2025 | 141187 | 0.600 |
Why?
| | Mutagens | 4 | 2019 | 24 | 0.580 |
Why?
| | Retrospective Studies | 23 | 2025 | 16273 | 0.540 |
Why?
| | Plant Preparations | 3 | 2025 | 37 | 0.540 |
Why?
| | Kidney Failure, Chronic | 1 | 2023 | 596 | 0.540 |
Why?
| | Treatment Outcome | 19 | 2025 | 11120 | 0.540 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 374 | 0.530 |
Why?
| | Exome | 1 | 2018 | 237 | 0.520 |
Why?
| | Infant | 21 | 2025 | 9818 | 0.520 |
Why?
| | Coronary Artery Disease | 2 | 2020 | 702 | 0.510 |
Why?
| | Prosthesis-Related Infections | 1 | 2017 | 99 | 0.500 |
Why?
| | Male | 46 | 2025 | 69783 | 0.500 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2017 | 528 | 0.490 |
Why?
| | Disease Management | 1 | 2020 | 633 | 0.490 |
Why?
| | Cardiomyopathy, Dilated | 4 | 2022 | 337 | 0.480 |
Why?
| | Extracorporeal Membrane Oxygenation | 4 | 2022 | 344 | 0.470 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 824 | 0.460 |
Why?
| | Risk Factors | 15 | 2024 | 10438 | 0.450 |
Why?
| | Cardiology | 1 | 2017 | 279 | 0.450 |
Why?
| | Stroke | 1 | 2023 | 1154 | 0.440 |
Why?
| | Follow-Up Studies | 9 | 2025 | 5200 | 0.430 |
Why?
| | High-Throughput Screening Assays | 5 | 2020 | 157 | 0.420 |
Why?
| | Myocardium | 3 | 2022 | 928 | 0.410 |
Why?
| | Benchmarking | 5 | 2024 | 188 | 0.410 |
Why?
| | Young Adult | 13 | 2024 | 13673 | 0.410 |
Why?
| | Sequence Analysis, RNA | 2 | 2014 | 450 | 0.390 |
Why?
| | Female | 35 | 2025 | 75515 | 0.390 |
Why?
| | Risk Assessment | 7 | 2025 | 3490 | 0.380 |
Why?
| | Consensus | 3 | 2025 | 704 | 0.360 |
Why?
| | Histones | 1 | 2017 | 639 | 0.360 |
Why?
| | Postoperative Complications | 6 | 2025 | 2797 | 0.350 |
Why?
| | Echocardiography | 3 | 2022 | 643 | 0.340 |
Why?
| | Gene Expression Regulation | 5 | 2025 | 2599 | 0.330 |
Why?
| | Mutation | 2 | 2019 | 4013 | 0.330 |
Why?
| | Dietary Supplements | 3 | 2019 | 566 | 0.330 |
Why?
| | Delivery of Health Care | 1 | 2017 | 961 | 0.330 |
Why?
| | Metabolomics | 4 | 2024 | 704 | 0.320 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2010 | 103 | 0.320 |
Why?
| | Waiting Lists | 4 | 2024 | 244 | 0.310 |
Why?
| | Computational Biology | 4 | 2025 | 661 | 0.310 |
Why?
| | Cimicifuga | 2 | 2019 | 2 | 0.300 |
Why?
| | Transforming Growth Factor alpha | 1 | 2009 | 57 | 0.300 |
Why?
| | Transplant Recipients | 4 | 2024 | 178 | 0.300 |
Why?
| | Databases, Factual | 5 | 2024 | 1444 | 0.280 |
Why?
| | Everolimus | 2 | 2025 | 110 | 0.280 |
Why?
| | Mycophenolic Acid | 2 | 2025 | 118 | 0.270 |
Why?
| | Genomics | 4 | 2023 | 814 | 0.260 |
Why?
| | Tacrolimus | 2 | 2025 | 198 | 0.260 |
Why?
| | Infant, Newborn | 11 | 2025 | 6275 | 0.250 |
Why?
| | Computer Simulation | 4 | 2021 | 1015 | 0.250 |
Why?
| | Formaldehyde | 2 | 2018 | 67 | 0.250 |
Why?
| | Ventricular Function, Left | 3 | 2022 | 513 | 0.250 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 497 | 0.250 |
Why?
| | DNA Damage | 3 | 2018 | 427 | 0.250 |
Why?
| | Plant Extracts | 2 | 2018 | 209 | 0.250 |
Why?
| | Survival Rate | 4 | 2025 | 1970 | 0.240 |
Why?
| | Incidence | 4 | 2025 | 2794 | 0.230 |
Why?
| | Stroke Volume | 4 | 2022 | 587 | 0.220 |
Why?
| | Interleukin-6 | 1 | 2009 | 792 | 0.220 |
Why?
| | Alkanesulfonic Acids | 1 | 2025 | 44 | 0.220 |
Why?
| | Time Factors | 6 | 2025 | 6956 | 0.220 |
Why?
| | Biotransformation | 1 | 2024 | 62 | 0.220 |
Why?
| | Aflatoxin B1 | 2 | 2014 | 2 | 0.220 |
Why?
| | Animals | 22 | 2025 | 37657 | 0.210 |
Why?
| | Rats | 9 | 2024 | 5629 | 0.210 |
Why?
| | Kidney | 2 | 2023 | 1482 | 0.210 |
Why?
| | Animal Testing Alternatives | 2 | 2021 | 3 | 0.210 |
Why?
| | DNA | 2 | 2019 | 1444 | 0.210 |
Why?
| | Multivariate Analysis | 4 | 2019 | 1490 | 0.210 |
Why?
| | Adverse Outcome Pathways | 1 | 2023 | 4 | 0.200 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1261 | 0.200 |
Why?
| | Fluorocarbons | 1 | 2025 | 121 | 0.200 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2025 | 2064 | 0.200 |
Why?
| | Vasoplegia | 1 | 2022 | 5 | 0.200 |
Why?
| | Heart Injuries | 1 | 2023 | 40 | 0.200 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2024 | 122 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 152 | 0.190 |
Why?
| | Muscular Dystrophies | 1 | 2022 | 35 | 0.190 |
Why?
| | Hep G2 Cells | 2 | 2025 | 71 | 0.190 |
Why?
| | Rodentia | 1 | 2022 | 59 | 0.190 |
Why?
| | American Heart Association | 2 | 2021 | 296 | 0.190 |
Why?
| | Ginkgo biloba | 2 | 2018 | 9 | 0.180 |
Why?
| | Organisation for Economic Co-Operation and Development | 1 | 2021 | 2 | 0.180 |
Why?
| | Hepatocytes | 2 | 2019 | 211 | 0.180 |
Why?
| | Structure-Activity Relationship | 3 | 2017 | 579 | 0.180 |
Why?
| | Mutagenicity Tests | 2 | 2019 | 13 | 0.170 |
Why?
| | Clinical Protocols | 1 | 2022 | 273 | 0.170 |
Why?
| | Databases, Chemical | 2 | 2019 | 9 | 0.170 |
Why?
| | Adult | 11 | 2024 | 39177 | 0.170 |
Why?
| | Pesticides | 1 | 2021 | 63 | 0.170 |
Why?
| | Coronary Vessels | 2 | 2021 | 247 | 0.170 |
Why?
| | Practice Patterns, Physicians' | 2 | 2021 | 1336 | 0.160 |
Why?
| | Echinacea | 1 | 2019 | 2 | 0.160 |
Why?
| | Age Factors | 4 | 2021 | 3292 | 0.160 |
Why?
| | Adjustment Disorders | 1 | 2019 | 5 | 0.160 |
Why?
| | Quantitative Structure-Activity Relationship | 2 | 2017 | 19 | 0.160 |
Why?
| | Stents | 1 | 2023 | 529 | 0.150 |
Why?
| | Arsenites | 1 | 2019 | 6 | 0.150 |
Why?
| | Spironolactone | 1 | 2019 | 34 | 0.150 |
Why?
| | Cohort Studies | 5 | 2024 | 5799 | 0.150 |
Why?
| | Logistic Models | 1 | 2024 | 2086 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 908 | 0.150 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 56 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 333 | 0.150 |
Why?
| | United States | 9 | 2022 | 15220 | 0.150 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 155 | 0.150 |
Why?
| | Food Contamination | 1 | 2018 | 55 | 0.150 |
Why?
| | Gene Amplification | 1 | 2019 | 103 | 0.150 |
Why?
| | Eugenol | 1 | 2018 | 4 | 0.150 |
Why?
| | Fontan Procedure | 1 | 2021 | 182 | 0.140 |
Why?
| | Tissue Fixation | 1 | 2018 | 37 | 0.140 |
Why?
| | Ultrasonography | 2 | 2020 | 755 | 0.140 |
Why?
| | Biomarkers | 7 | 2018 | 4174 | 0.140 |
Why?
| | Paraffin Embedding | 1 | 2018 | 33 | 0.140 |
Why?
| | Coronary Angiography | 1 | 2020 | 316 | 0.140 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 158 | 0.140 |
Why?
| | HEK293 Cells | 2 | 2018 | 737 | 0.140 |
Why?
| | Prostate | 1 | 2019 | 173 | 0.140 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 263 | 0.140 |
Why?
| | Mice, Inbred Strains | 1 | 2018 | 412 | 0.140 |
Why?
| | Isoantibodies | 1 | 2017 | 55 | 0.130 |
Why?
| | Cell Culture Techniques | 2 | 2017 | 368 | 0.130 |
Why?
| | Cryopreservation | 1 | 2018 | 106 | 0.130 |
Why?
| | Global Health | 1 | 2020 | 386 | 0.130 |
Why?
| | Patient Selection | 1 | 2021 | 688 | 0.130 |
Why?
| | Uniparental Disomy | 1 | 2017 | 9 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2902 | 0.130 |
Why?
| | Donor Selection | 1 | 2017 | 75 | 0.130 |
Why?
| | Artificial Intelligence | 1 | 2021 | 334 | 0.130 |
Why?
| | Anesthesia, Dental | 1 | 2017 | 22 | 0.130 |
Why?
| | Bundle-Branch Block | 1 | 2017 | 30 | 0.130 |
Why?
| | Tooth Extraction | 1 | 2017 | 25 | 0.130 |
Why?
| | Epigenomics | 1 | 2017 | 114 | 0.130 |
Why?
| | Arsenic | 1 | 2017 | 63 | 0.130 |
Why?
| | Gene Expression | 2 | 2019 | 1491 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 112 | 0.130 |
Why?
| | Research Design | 2 | 2023 | 1143 | 0.130 |
Why?
| | DNA Repair | 2 | 2019 | 234 | 0.130 |
Why?
| | Education, Medical, Continuing | 1 | 2017 | 133 | 0.130 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3348 | 0.120 |
Why?
| | HLA Antigens | 1 | 2017 | 233 | 0.120 |
Why?
| | Depressive Disorder | 1 | 2019 | 394 | 0.120 |
Why?
| | Systems Biology | 1 | 2016 | 70 | 0.120 |
Why?
| | Models, Chemical | 1 | 2017 | 272 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1498 | 0.120 |
Why?
| | Trisomy | 1 | 2017 | 79 | 0.120 |
Why?
| | Anesthesia, General | 1 | 2017 | 117 | 0.120 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2017 | 135 | 0.120 |
Why?
| | Cluster Analysis | 1 | 2017 | 521 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2018 | 761 | 0.120 |
Why?
| | Neuromuscular Diseases | 1 | 2017 | 129 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2020 | 533 | 0.120 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 286 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2019 | 585 | 0.120 |
Why?
| | Heme Oxygenase-1 | 1 | 2015 | 64 | 0.120 |
Why?
| | Gene-Environment Interaction | 2 | 2017 | 187 | 0.110 |
Why?
| | Aromatase Inhibitors | 1 | 2015 | 58 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2018 | 412 | 0.110 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 178 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2024 | 2828 | 0.110 |
Why?
| | Equipment Failure | 1 | 2015 | 111 | 0.110 |
Why?
| | Biomarkers, Pharmacological | 1 | 2014 | 26 | 0.110 |
Why?
| | Perioperative Care | 1 | 2017 | 227 | 0.110 |
Why?
| | Freezing | 1 | 2014 | 88 | 0.110 |
Why?
| | Rats, Inbred F344 | 1 | 2014 | 269 | 0.110 |
Why?
| | Vaccination | 4 | 2024 | 1467 | 0.100 |
Why?
| | Cell Survival | 1 | 2017 | 1129 | 0.100 |
Why?
| | Crohn Disease | 1 | 2017 | 254 | 0.100 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 531 | 0.100 |
Why?
| | Cell Membrane | 1 | 2017 | 724 | 0.100 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.100 |
Why?
| | Dexmedetomidine | 1 | 2013 | 43 | 0.100 |
Why?
| | Propensity Score | 1 | 2015 | 328 | 0.100 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 771 | 0.100 |
Why?
| | Proteome | 1 | 2017 | 483 | 0.100 |
Why?
| | Hemodynamics | 2 | 2018 | 1100 | 0.100 |
Why?
| | Epithelial Cells | 1 | 2019 | 1110 | 0.100 |
Why?
| | Disease Progression | 1 | 2020 | 2793 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1244 | 0.090 |
Why?
| | Heart | 2 | 2022 | 620 | 0.090 |
Why?
| | Genetic Diseases, Inborn | 1 | 2012 | 46 | 0.090 |
Why?
| | Anxiety | 1 | 2019 | 1082 | 0.090 |
Why?
| | Hospitalization | 1 | 2022 | 2255 | 0.090 |
Why?
| | Mental Disorders | 1 | 2020 | 1120 | 0.090 |
Why?
| | Models, Genetic | 1 | 2014 | 591 | 0.090 |
Why?
| | Respiratory Insufficiency | 1 | 2015 | 326 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2025 | 1040 | 0.090 |
Why?
| | Kidney Diseases | 1 | 2015 | 406 | 0.090 |
Why?
| | Recovery of Function | 1 | 2015 | 678 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 878 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 666 | 0.080 |
Why?
| | Antibody Formation | 2 | 2022 | 298 | 0.080 |
Why?
| | Oxidative Stress | 1 | 2017 | 1330 | 0.080 |
Why?
| | Propanolamines | 1 | 2010 | 39 | 0.080 |
Why?
| | Carbazoles | 1 | 2010 | 56 | 0.080 |
Why?
| | Pediatrics | 1 | 2018 | 1094 | 0.080 |
Why?
| | Prognosis | 3 | 2018 | 4073 | 0.080 |
Why?
| | Signal Transduction | 3 | 2018 | 5144 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 2070 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2014 | 1973 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2504 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2010 | 434 | 0.080 |
Why?
| | Carcinogenicity Tests | 2 | 2022 | 10 | 0.080 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 521 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5929 | 0.070 |
Why?
| | Multicenter Studies as Topic | 1 | 2010 | 338 | 0.070 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 228 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2024 | 653 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2017 | 1556 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 689 | 0.070 |
Why?
| | Survival Analysis | 1 | 2011 | 1319 | 0.070 |
Why?
| | Transplantation, Homologous | 1 | 2009 | 413 | 0.070 |
Why?
| | Biological Assay | 2 | 2018 | 131 | 0.070 |
Why?
| | RNA | 1 | 2014 | 930 | 0.070 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2007 | 16 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 77 | 0.070 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2019 | 57 | 0.060 |
Why?
| | Genotype | 2 | 2009 | 1859 | 0.060 |
Why?
| | Neoplasms | 1 | 2022 | 2741 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 2 | 2024 | 2520 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1056 | 0.060 |
Why?
| | Hemofiltration | 1 | 2006 | 23 | 0.060 |
Why?
| | Biopsy | 1 | 2009 | 1081 | 0.060 |
Why?
| | Lymphoproliferative Disorders | 1 | 2025 | 60 | 0.060 |
Why?
| | ROC Curve | 2 | 2019 | 586 | 0.060 |
Why?
| | Exons | 2 | 2019 | 353 | 0.060 |
Why?
| | Caprylates | 1 | 2025 | 28 | 0.060 |
Why?
| | Aged | 2 | 2023 | 24574 | 0.060 |
Why?
| | Catheterization, Peripheral | 1 | 2006 | 108 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2007 | 625 | 0.050 |
Why?
| | Catheterization, Central Venous | 1 | 2006 | 116 | 0.050 |
Why?
| | Gene Regulatory Networks | 2 | 2019 | 313 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 197 | 0.050 |
Why?
| | Workflow | 1 | 2025 | 171 | 0.050 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2023 | 41 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2018 | 2526 | 0.050 |
Why?
| | Prospective Studies | 4 | 2020 | 7739 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 156 | 0.050 |
Why?
| | Cell Line | 2 | 2019 | 2885 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 546 | 0.050 |
Why?
| | Hypertension, Pulmonary | 1 | 2013 | 1936 | 0.050 |
Why?
| | Antibodies | 1 | 2024 | 409 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 139 | 0.050 |
Why?
| | Replantation | 1 | 2021 | 31 | 0.040 |
Why?
| | Bias | 1 | 2022 | 229 | 0.040 |
Why?
| | Insurance Coverage | 1 | 2022 | 237 | 0.040 |
Why?
| | Data Accuracy | 1 | 2021 | 65 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 287 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 198 | 0.040 |
Why?
| | Middle Aged | 2 | 2021 | 34434 | 0.040 |
Why?
| | Social Class | 1 | 2022 | 268 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2022 | 215 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2019 | 4208 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2022 | 280 | 0.040 |
Why?
| | PPAR alpha | 1 | 2019 | 57 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 5636 | 0.040 |
Why?
| | Carcinogens, Environmental | 1 | 2019 | 14 | 0.040 |
Why?
| | Documentation | 1 | 2021 | 199 | 0.040 |
Why?
| | Cricetulus | 1 | 2019 | 111 | 0.040 |
Why?
| | CHO Cells | 1 | 2019 | 168 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 171 | 0.040 |
Why?
| | Chickens | 1 | 2019 | 189 | 0.040 |
Why?
| | DNA Breaks, Double-Stranded | 1 | 2019 | 47 | 0.040 |
Why?
| | Micronucleus Tests | 1 | 2018 | 7 | 0.040 |
Why?
| | Therapeutic Equivalency | 1 | 2018 | 32 | 0.040 |
Why?
| | Anemia, Megaloblastic | 1 | 2018 | 9 | 0.040 |
Why?
| | Micronuclei, Chromosome-Defective | 1 | 2018 | 8 | 0.040 |
Why?
| | Hyperplasia | 1 | 2018 | 176 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2019 | 209 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2019 | 303 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2018 | 41 | 0.030 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 209 | 0.030 |
Why?
| | Muscular Dystrophy, Emery-Dreifuss | 1 | 2017 | 3 | 0.030 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2017 | 6 | 0.030 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 1 | 2017 | 6 | 0.030 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2019 | 245 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2021 | 739 | 0.030 |
Why?
| | Barth Syndrome | 1 | 2017 | 8 | 0.030 |
Why?
| | Activation, Metabolic | 1 | 2017 | 5 | 0.030 |
Why?
| | Phytotherapy | 1 | 2018 | 82 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 203 | 0.030 |
Why?
| | Myotonic Dystrophy | 1 | 2017 | 10 | 0.030 |
Why?
| | Antidepressive Agents | 1 | 2019 | 254 | 0.030 |
Why?
| | HCT116 Cells | 1 | 2017 | 80 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2018 | 196 | 0.030 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 2017 | 39 | 0.030 |
Why?
| | Brazil | 1 | 2017 | 173 | 0.030 |
Why?
| | Infliximab | 1 | 2017 | 111 | 0.030 |
Why?
| | Hazardous Substances | 1 | 2016 | 17 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2017 | 67 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2017 | 147 | 0.030 |
Why?
| | Sample Size | 1 | 2017 | 128 | 0.030 |
Why?
| | Death | 1 | 2017 | 125 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2018 | 242 | 0.030 |
Why?
| | Folic Acid | 1 | 2018 | 195 | 0.030 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 46 | 0.030 |
Why?
| | DNA Methylation | 1 | 2021 | 645 | 0.030 |
Why?
| | Mosaicism | 1 | 2017 | 74 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 322 | 0.030 |
Why?
| | Friedreich Ataxia | 1 | 2017 | 78 | 0.030 |
Why?
| | Pulsatile Flow | 1 | 2016 | 55 | 0.030 |
Why?
| | Echocardiography, Transesophageal | 1 | 2017 | 128 | 0.030 |
Why?
| | Canada | 1 | 2017 | 428 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 358 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1662 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2017 | 565 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2022 | 1251 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2015 | 126 | 0.030 |
Why?
| | Catheters | 1 | 2015 | 74 | 0.030 |
Why?
| | Colonoscopy | 1 | 2017 | 250 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2015 | 95 | 0.030 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2014 | 17 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2019 | 1983 | 0.030 |
Why?
| | Kidney Tubules, Proximal | 1 | 2015 | 132 | 0.030 |
Why?
| | Tissue Donors | 1 | 2017 | 405 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2014 | 32 | 0.030 |
Why?
| | Gene Library | 1 | 2014 | 120 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 346 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 312 | 0.030 |
Why?
| | Area Under Curve | 1 | 2014 | 324 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2021 | 3588 | 0.030 |
Why?
| | Electrocardiography | 1 | 2017 | 618 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2017 | 1197 | 0.030 |
Why?
| | Glucuronosyltransferase | 1 | 2013 | 17 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1242 | 0.020 |
Why?
| | E2F1 Transcription Factor | 1 | 2013 | 68 | 0.020 |
Why?
| | Radiation Effects | 1 | 2012 | 7 | 0.020 |
Why?
| | Genetic Variation | 1 | 2018 | 1000 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2013 | 194 | 0.020 |
Why?
| | Erythrocytes | 1 | 2018 | 699 | 0.020 |
Why?
| | Alternative Splicing | 1 | 2014 | 232 | 0.020 |
Why?
| | Acute Disease | 1 | 2015 | 1008 | 0.020 |
Why?
| | Models, Molecular | 1 | 2017 | 1603 | 0.020 |
Why?
| | Estradiol | 1 | 2015 | 528 | 0.020 |
Why?
| | Testosterone | 1 | 2015 | 404 | 0.020 |
Why?
| | Germ-Line Mutation | 1 | 2012 | 167 | 0.020 |
Why?
| | Precancerous Conditions | 1 | 2013 | 166 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2019 | 3469 | 0.020 |
Why?
| | Tobacco Products | 1 | 2012 | 129 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2892 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2999 | 0.020 |
Why?
| | Heart Ventricles | 1 | 2015 | 752 | 0.020 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2013 | 353 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 1171 | 0.020 |
Why?
| | Lung | 1 | 2021 | 4134 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2007 | 119 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2007 | 113 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1431 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2009 | 573 | 0.020 |
Why?
| | DNA Primers | 1 | 2007 | 510 | 0.020 |
Why?
| | Gene Frequency | 1 | 2007 | 494 | 0.020 |
Why?
| | Subclavian Vein | 1 | 2006 | 15 | 0.020 |
Why?
| | Pregnancy | 1 | 2017 | 7070 | 0.010 |
Why?
| | Alleles | 1 | 2007 | 891 | 0.010 |
Why?
| | Base Sequence | 1 | 2007 | 2180 | 0.010 |
Why?
| | Mice | 1 | 2018 | 18048 | 0.010 |
Why?
| | Phenotype | 1 | 2007 | 3166 | 0.010 |
Why?
|
|
Auerbach's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|